Training cohort | Validation cohort | |||
---|---|---|---|---|
RA (before 1 May 2016) | Control (before 1 May 2016) | RA (after 16 May 2016) | non-RA (after 16 May 2016) | |
Sex (female/male), n | 80/18 | 50/53 | 174/43 | 187/168 |
Age (years) | 58 (27, 85) | 49 (19, 86) | 59 (15, 84) | 48 (13, 94) |
Symptom duration (years) | 10 (0.01, 50) | NA | 5 (0.01, 50) | 4 (0.01, 50) |
CRP (mg/L) | 22 (0.6, 331) | NA | 18.6 (0.16, 339) | 8.0 (0.16, 436) |
ESR (mm/h) | 44 (2, 140) | NA | 42 (2, 134) | 24 (2, 120) |
ACPA positive, n (%) | 71 (72) | NA | 147(68) | 12 (3) |
RF positive, n (%) | 65 (66) | NA | 136 (63) | 63 (18) |
Serum CTGF (pg/mL) | 293.9 (7.87, 1285) | 30 (0.16, 171.3) | 289.2 (1.82, 2351) | 22.45 (0.12, 541) |
Synovial fluid CTGF (pg/mL) | 534 (1.55, 2574) | 23.87 (2.65, 166.8) | NA | NA |